Nathalie Garçon, PharmD, PhD
Dr. Nathalie Garçon is currently the chief executive (CEO) and scientific officer (CSO) of BIOASTER. Prior to joining BIOASTER, Dr. Garçon held several positions within SmithKline Beecham Biologicals, now known as GlaxoSmithKline Vaccines, including Vice President, Head of global vaccine center for adjuvants and technology innovation, Vice President, head of Research and North America R&D, Director of research and new technologies R&D, and Director of alternative deliveries and preclinical operations. She is a biological Pharmacist by training, which included two doctoral dissertations, one in pharmaceutical science and another in immunotoxicology and immunopharmacology from Claude Bernard Lyon 1, which is part of the Université de Lyon.
Dr. Garçon's expertise in vaccinology extends from research to manufacturing, in particular immunology, adjuvant and formulation technologies, analytical methods, animal experimentation and toxicology/safety evaluation and testing. Dr. Garçon is the 2014 laureate of the Stanley Plotkin award for lifetime achievement in the field of vaccines and vaccine technologies. She has authored over 80 papers and book chapters, and is listed as inventor on more than 100 patents. Dr. Garçon is an active member of ISV, including poster presentations and serving as a keynote speaker. She served on the scientific committee for the 2015 and 2017 ISV Congresses and participated in the mentoring sessions.